Apyx Medical 2025 Q3 Earnings 58.6% Net Loss Reduction and 12.1% Revenue Growth

, . , reflecting confidence in its growth trajectory despite sustained losses.

Revenue

, , attributable to the AYON system’s commercial launch. Conversely, . , .

Earnings/Net Income

, . , . , signaling progress in financial recovery.

Post-Earnings Price Action Review

. , , remaining within its 52-week range. . Historical volatility persisted, but the long-term outlook remains optimistic, supported by product innovation and strategic resource reallocation.

CEO Commentary

CEO highlighted the full U.S. commercial launch of AYON, . He emphasized accelerating AYON adoption and expanding its user base, .

Guidance

, . , reflecting disciplined cost management.

Additional News

1. Strategic Rebranding

2. Regulatory Milestone, .

3. , prioritizing long-term growth in its core product lines.

[Generated by Automated Insights]